637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome

241 ASH denotes this abstract as clinically relevant

Jacqueline S. Garcia, Andrew H. Wei, Meagan A. Jacoby, et al.In MDS with a higher risk, Venetoclax plus Azacitidine leads to a rapid and sustained response and high remission rates. Meaningful clinical and molecular responses were observed in all major mutation profiles. Updated data will be presented in the oral session.


243 ASH denotes this abstract as clinically relevant

Pierre Peterlin, Pascal Turlure, Patrice Chevallier, et al.

The study authors show that CPX-351 is effective for MDS/CMML with higher risk. This is particularly true for achieving blast clearance and as a bridge to allo SCT.


244 ASH denotes this abstract as clinically relevant

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, et al.

Sabatolimab + HMA demonstrated a sustained clinical response in patients with vHR / HR-MDS and ND-AM. According to the study authors, the combination is safe and well-tolerated.



Sangeetha Venugopal, Hagop Kantarjian, Abhishek Maiti, et al.

The combination Venetoclax + ASTX727 (cedazuridine/decitabine) appears to be safe according to the study authors. It demonstrates preliminary efficacy in patients with MDS or CMML at increased risk and excess blasts.



David A. Sallman, Rami S. Komrokji, Amy E. DeZern, et al.

Treatment of eprenetapopt (APR-246) and azacitidine (AZA) in mTP53 MDS/AML was well tolerated and high response rates were achieved.